New York Eye and Ear Infirmary of Mount Sinai is offering the latest advancements in the treatment of progressive keratoconus and corneal ectasia after refractive surgery. The corneal collagen cross-linking technology, approved by the FDA for use in the United States in April 2016, was used for the first time at the Laser Vision Correction Center at New York Eye and Ear Infirmary in February 2017. Avedro’s corneal cross-linking device is the only FDA approved corneal cross-linking device in the United States.
Corneal collagen cross-linking is a minimally invasive procedure that uses riboflavin, a type of B vitamin, and ulatrviolet (UV) light to strengthen chemical bonds in the cornea. The goal of the new treatment is to halt progressive changes in the corneal shape known as ectasia that is most often seen in keratoconus patients or as a complication after laser vision correction.
Patients diagnosed with keratoconus experience changes in the cornea shape; the bulging creates an abnormal curvature that changes the cornea’s optics, producing blurred and distorted vision, thinning of the cornea, and irregular astigmatism. The best candidates for cornea cross-linking are patients with minimal changes to the cornea shape and who do not have significant vision loss from keratoconus. If applied in the early stages of the disease, CXL can stabilize the shape of the cornea, resulting in better vision and an improved ability to wear contact lenses. In addition, by halting the progression of corneal ectasia, patients can reduce the need for a possible corneal transplant if the condition remains unchecked.